Combination drug delivery approach as an effective therapy for various diseases /

Bibliographic Details
Other Authors: Kesharwani, Prashant
Format: Book
Language:English
Published: London : Academic Press, 2022
Subjects:
LEADER 04598nam a2200433Ia 4500
001 77ebb7c6-c9b9-421b-8971-23a551ac0129
005 20240926000000.0
008 220330s2022 enk o 000 0 eng d
020 |a 0323858767  |q (electronic bk.) 
020 |a 9780323858762  |q (electronic bk.) 
020 |z 0323858732 
020 |z 9780323858731 
035 |a (OCoLC)1306276987 
035 |a (Sirsi) a14214077 
035 |a (Sirsi) eson1306276987 
040 |a YDX  |b eng  |c YDX  |d OPELS  |d EBLCP  |d OCLCO  |d OCLCF  |d CSt 
050 4 |a RS199.5 
082 0 4 |a 615/.6  |2 23 
245 0 0 |a Combination drug delivery approach as an effective therapy for various diseases /  |c edited by Prashant Kesharwani 
260 |a London :  |b Academic Press,  |c 2022 
300 |a 1 online resource 
505 0 |a Front Cover -- Combination Drug Delivery Approach as an Effective Therapy for Various Diseases -- Copyright Page -- Dedication -- Contents -- List of contributors -- Preface -- Acknowledgments -- A. Combination drug delivery approaches against various diseases -- 1 Overcoming cancer drug resistance via nanomedicine-based combined drug delivery -- 1.1 Introduction -- 1.2 Organic nanocarriers -- 1.2.1 Lipid-based systems -- 1.2.1.1 Liposomal formulations -- 1.2.1.2 Solid lipid nanoparticles -- 1.2.1.3 Nanostructured lipid carriers -- 1.2.1.4 Nanoemulsion -- 1.2.2 Protein-based nanocarriers 
505 8 |a 1.2.3 Polymeric nanoparticles -- 1.3 Inorganic nanocarriers -- 1.3.1 Iron oxide nanoparticles -- 1.3.2 Quantum dots -- 1.3.3 Gold nanoparticles -- 1.3.4 Mesoporous silica nanoparticles -- 1.3.5 Carbon-based nanocarriers -- 1.3.5.1 Graphene -- 1.3.5.2 Carbon nanotubes -- 1.4 Conclusion -- References -- 2 Overcoming the challenges of drug resistance through combination drug delivery approach -- 2.1 Introduction -- 2.2 Drug resistance in cancer -- 2.2.1 Intrinsic and acquired drug resistance -- 2.2.2 Mechanisms of drug resistance -- 2.2.2.1 Elevated drug efflux -- 2.2.2.2 Tumor microenvironment 
505 8 |a 2.2.2.3 Enhanced DNA repair -- 2.2.2.4 Other mechanisms -- 2.2.3 Combinational drug delivery systems in cancer drug resistance -- 2.2.3.1 Nanoparticulate drug delivery systems -- 2.2.4 Combinational therapies via nanoparticulate systems -- 2.2.4.1 Combination of different chemotherapeutics -- 2.2.4.2 Combination of chemotherapeutics and sensitizing agents -- 2.2.4.2.1 P-gp inhibitors -- 2.2.4.2.2 Autophagy inhibitors -- 2.2.4.3 Combination of chemotherapeutics and genes -- 2.2.4.3.1 Plasmid DNA -- 2.2.4.3.2 RNAs -- 2.2.4.4 Combination of chemotherapeutics and protein-based molecules 
505 8 |a 2.2.4.4.1 Antibodies -- 2.2.4.4.2 Peptides and proteins -- 2.2.5 Conclusion -- 2.3 Combination drug delivery approach to overcome antimicrobial resistance -- 2.4 Conclusion -- References -- 3 Combination drug delivery approaches in ophthalmology -- 3.1 The eye -- 3.2 The need for new ophthalmic treatments -- 3.2.1 Increasing prevalence of ocular diseases -- 3.2.1.1 Age as risk factor -- 3.2.1.2 Susceptibility to exogenous threats -- 3.2.1.3 Refractive surgery for myopia -- 3.2.2 The difficulty of drugs to reach their intraocular target 
505 8 |a 3.2.3 Adverse ocular effects of topically administered drugs -- 3.3 Drug-device combinations in ophthalmology -- 3.3.1 Drug-device combinations for glaucoma -- 3.3.2 Drug-device combinations for surgeries -- 3.3.3 Drug-device combinations for ocular infections and inflammations -- 3.3.4 Drug-device combinations for dry eye disease -- 3.4 Challenges and future perspectives -- References -- 4 Combination drug delivery system to enhance the transdermal drug delivery of bioactive molecules -- 4.1 Introduction -- 4.2 Physiological skin row versus percutaneous permeation of bioactive molecules 
650 0 |a Chemotherapy 
650 0 |a Drug delivery systems 
650 2 |a Drug Delivery Systems 
650 2 |a Drug Therapy 
650 6 |a Chimiothérapie 
650 6 |a Systèmes d'administration de médicaments 
650 7 |a Chemotherapy  |2 fast 
650 7 |a Drug delivery systems  |2 fast 
700 1 |a Kesharwani, Prashant 
776 0 8 |c Original  |z 0323858732  |z 9780323858731  |w (OCoLC)1268112830 
999 1 0 |i 77ebb7c6-c9b9-421b-8971-23a551ac0129  |l a14214077  |s US-CST  |m combination_drug_delivery_approach_as_an_effective_therapy_for_various_____2022_______acadea___________________________________________________________________________e 
999 1 1 |l a14214077  |s ISIL:US-CST  |t BKS  |b a71155e9-4d29-580f-a93e-25a63d790497  |y a71155e9-4d29-580f-a93e-25a63d790497  |p UNLOANABLE 
999 1 1 |l a14214077  |s ISIL:US-CST  |t BKS  |a SUL-ELECTRONIC  |p UNLOANABLE